We are live on ! Find out more
NVAX icon

Novavax

201 hedge funds and large institutions have $371M invested in Novavax in 2024 Q1 according to their latest regulatory filings, with 32 funds opening new positions, 73 increasing their positions, 43 reducing their positions, and 28 closing their positions.

New
Increased
Maintained
Reduced
Closed

125% more call options, than puts

Call options by funds: $214M | Put options by funds: $94.8M

70% more repeat investments, than reductions

Existing positions increased: 73 | Existing positions reduced: 43

14% more first-time investments, than exits

New positions opened: 32 | Existing positions closed: 28

1% more funds holding

Funds holding: 199201 (+2)

0% more funds holding in top 10

Funds holding in top 10: 11 (0)

10% less capital invested

Capital invested by funds: $411M → $371M (-$39.4M)

16.64% less ownership

Funds ownership: 71.6%54.96% (-17%)

Holders
201
Holders Change
+2
Holders Change %
+1.01%
% of All Funds
2.9%
Holding in Top 10
1
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.01%
New
32
Increased
73
Reduced
43
Closed
28
Calls
$214M
Puts
$94.8M
Net Calls
+$119M
Net Calls Change
+$118M
Name Holding Trade Value Shares
Change
Change in
Stake
NSIM
226
North Star Investment Management
Illinois
-$106 -22 Closed
GWS
227
Glassman Wealth Services
Virginia
-$62 -13 Closed
Macquarie Group
228
Macquarie Group
Australia
+$42 +9 New

NVAX Hedge Fund Activity: Q1 2024 in Review

201 of the 6,942 institutional investors tracked by Wall St. Rank reported a position in Novavax (NVAX) for Q1 2024, worth a combined $371M — down 9.6% from $411M a quarter earlier.

Buyers outnumbered sellers: 32 funds opened new NVAX positions and 28 closed out — a net gain of 4 holders — while 73 added to existing stakes and 43 trimmed.

The largest buyer was Farallon Capital Management, opening a new position worth an estimated $5.25M. The largest seller was Morgan Stanley, cutting an estimated $58.5M.

  • 201 institutional investors held Novavax (NVAX) as of Q1 2024, up from 199 in Q4 2023.
  • Funds reported $371M of Novavax stock for Q1 2024, down 9.6% quarter-over-quarter.
  • 32 funds opened new Novavax positions in Q1 2024 and 28 closed out, a net change of +4 holders.
  • The largest Novavax buyer in Q1 2024 was Farallon Capital Management, an estimated $5.25M added.
  • The largest Novavax seller in Q1 2024 was Morgan Stanley, an estimated $58.5M sold.

Based on aggregated 13F filings for Q1 2024.